Physician profile
Khavar Dar
NPI 1669449617
$583.91
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $130.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $150.87 | 2019-2020 | |
| Novo Nordisk INC | $101.94 | 2019-2020 | |
| Glaxosmithkline, LLC. | $63.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.07 | 2019 | |
| Lilly USA, LLC | $51.86 | 2019-2020 | |
| Allergan, INC. | $42.04 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.42 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $33.85 | 2019 | |
| Mylan Specialty L.P. | $19.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khavar Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.